These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 7764801)

  • 1. Large-scale processing of macromolecules.
    Fulton SP
    Curr Opin Biotechnol; 1994 Feb; 5(2):201-5. PubMed ID: 7764801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precipitation as an Enabling Technology for the Intensification of Biopharmaceutical Manufacture.
    Martinez M; Spitali M; Norrant EL; Bracewell DG
    Trends Biotechnol; 2019 Mar; 37(3):237-241. PubMed ID: 30316558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous downstream processing of biopharmaceuticals.
    Jungbauer A
    Trends Biotechnol; 2013 Aug; 31(8):479-92. PubMed ID: 23849674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous downstream processing for high value biological products: A Review.
    Zydney AL
    Biotechnol Bioeng; 2016 Mar; 113(3):465-75. PubMed ID: 26153056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromatographic purification of recombinant human erythropoietin.
    Adamíková J; Antošová M; Polakovič M
    Biotechnol Lett; 2019 May; 41(4-5):483-493. PubMed ID: 30810853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing.
    Fisher AC; Kamga MH; Agarabi C; Brorson K; Lee SL; Yoon S
    Trends Biotechnol; 2019 Mar; 37(3):253-267. PubMed ID: 30241924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An impurity characterization based approach for the rapid development of integrated downstream purification processes.
    Timmick SM; Vecchiarello N; Goodwine C; Crowell LE; Love KR; Love JC; Cramer SM
    Biotechnol Bioeng; 2018 Aug; 115(8):2048-2060. PubMed ID: 29679482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational and systematic protein purification process development: the next generation.
    Nfor BK; Verhaert PD; van der Wielen LA; Hubbuch J; Ottens M
    Trends Biotechnol; 2009 Dec; 27(12):673-9. PubMed ID: 19815300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-scale processing & high-throughput perfusion chromatography.
    Fulton SP; Shahidi AJ; Gordon NF; Afeyan NB
    Biotechnology (N Y); 1992 Jun; 10(6):635-9. PubMed ID: 1368883
    [No Abstract]   [Full Text] [Related]  

  • 10. Micro biochemical engineering to accelerate the design of industrial-scale downstream processes for biopharmaceutical proteins.
    Titchener-Hooker NJ; Dunnill P; Hoare M
    Biotechnol Bioeng; 2008 Jun; 100(3):473-87. PubMed ID: 18438873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in affinity ligand-functionalized nanomaterials for biomagnetic separation.
    Fields C; Li P; O'Mahony JJ; Lee GU
    Biotechnol Bioeng; 2016 Jan; 113(1):11-25. PubMed ID: 26032605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of industrial bioprocessing: batch or continuous?
    Croughan MS; Konstantinov KB; Cooney C
    Biotechnol Bioeng; 2015 Apr; 112(4):648-51. PubMed ID: 25694022
    [No Abstract]   [Full Text] [Related]  

  • 13. Multistage magnetic and electrophoretic extraction of cells, particles and macromolecules.
    Raghavarao KS; Dueser M; Todd P
    Adv Biochem Eng Biotechnol; 2000; 68():139-90. PubMed ID: 11036687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of semi-selective protein precipitation with salt-tolerant copolymers for industrial purification of therapeutic antibodies.
    Capito F; Bauer J; Rapp A; Schröter C; Kolmar H; Stanislawski B
    Biotechnol Bioeng; 2013 Nov; 110(11):2915-27. PubMed ID: 23637026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current state-of-the-art in plant-based antibody production systems.
    Donini M; Marusic C
    Biotechnol Lett; 2019 Mar; 41(3):335-346. PubMed ID: 30684155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of difficult-to-remove host cell protein impurities during extended Chinese hamster ovary cell culture and their impact on continuous bioprocessing.
    Valente KN; Lenhoff AM; Lee KH
    Biotechnol Bioeng; 2015 Jun; 112(6):1232-42. PubMed ID: 25502542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High throughput screening of particle conditioning operations: I. System design and method development.
    Noyes A; Huffman B; Godavarti R; Titchener-Hooker N; Coffman J; Sunasara K; Mukhopadhyay T
    Biotechnol Bioeng; 2015 Aug; 112(8):1554-67. PubMed ID: 25728932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant plant-derived pharmaceutical proteins: current technical and economic bottlenecks.
    Sabalza M; Christou P; Capell T
    Biotechnol Lett; 2014 Dec; 36(12):2367-79. PubMed ID: 25048244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host cell proteins in biotechnology-derived products: A risk assessment framework.
    de Zafra CL; Quarmby V; Francissen K; Vanderlaan M; Zhu-Shimoni J
    Biotechnol Bioeng; 2015 Nov; 112(11):2284-91. PubMed ID: 26010760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.